Teaneck, NJ (PRWEB) July 30, 2016 -- This approval supplements the recent approval of crosslinking to treat keratoconus. Approval was granted to Avedro, Inc. for Photrexa Viscous, Photrexa and the KXL System. Collagen crosslinking uses a combination of riboflavin (a form of vitamin B2) and ultraviolet light. When used in the approved fashion, the goal of crosslinking is to make the cornea stronger, to decrease the progression of corneal ectasia.Dr. Peter S. Hersh, M.D., founder of the Cornea and Laser Eye Institute and its CLEI Center for Keratoconus was medical monitor of the clinical trial which led to this approval. About Keratoconus and Corneal EctasiaKeratoconus and corneal ectasia are similar eye disorders that result in thinning of the cornea, the front surface lens of the eye. Consequently, the cornea bulges out of its smooth, clear, dome-like structure, and assumes a more conical and irregular configuration. This irregularity tends to worsen over time.Because of this change in shape, the cornea loses its ability to form a clear image in the eye and the patient's vision can decrease drastically. Often, in the past, patient’s required corneal transplantation as the corneal warpage worsened. CXL offers the hope of slowing this progression and thus avoiding the need for transplantation. About the CLEI Center for KeratoconusDr. Peter S. Hersh, M.D, director of the Cornea and Laser Eye Institute - Hersh Vision Group inaugurated its subspecialty dedicated CLEI Center for Keratoconus in 2002. Dr. Hersh is a graduate of Princeton University, Johns Hopkins Medical School, and Harvard Medical School's ophthalmology residency and corneal surgery fellowship programs. The mission of the CLEI Center for Keratoconus is to provide the keratoconus patient with expert and state-of-the-art diagnostic, therapeutic, and surgical services covering all aspects of keratoconic and corneal ectasia care. With doctors and surgeons expert in corneal disease, specialty contact lens fittings, and the full range of innovative corneal and refractive surgery procedures for the treatment of keratoconus and corneal ectasia, patients receive examinations to fully assess their problem and can be offered the best treatment options available. With a full-time clinical research director, the CLEI Center for Keratoconus is also at the forefront of research and innovation in keratoconus and ectasia treatments. In addition to monitoring the study leading to recent approval of the crosslinking technique, Dr. Hersh and the centers team perform a number of research studies and clinical trials designed to afford the keratoconus and ectasia patient the most up-to-date and advanced care available.
Stacey Lazar, The CLEI Center for Keratoconus, http://www.keratoconuscenter.com, +1 (201) 692-9434, [email protected]